New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT07369505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side effects. About 27 participants will receive weekly intravenous doses to guide future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SOCRU
RECRUITINGAdelaide, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- AI-Powered surveillance may outsmart liver cancer recurrence